marimastat
Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor. — Wikipedia
Clinical trial activity
4 trials · 10 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 1996 (NCT00002911)
Timeline
Indications
Mechanism of action
- Matrix metalloproteinase 7INHIBITOR
MMP7 inhibitor
Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.
- Matrix metalloproteinase-2INHIBITOR
MMP2 inhibitor
Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.
- Matrix metalloproteinase 3INHIBITOR
MMP3 inhibitor
Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.
- Matrix metalloproteinase 12INHIBITOR
MMP12 inhibitor
Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.
- Matrix metalloproteinase 9INHIBITOR
MMP9 inhibitor
Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.
- Matrix metalloproteinase-1INHIBITOR
MMP1 inhibitor
Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.
Chemistry & pharmacology
SMILES
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C- Mol. weight
- 331.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMarimastat ↗
- ChEMBLCHEMBL279785 ↗
Also known as
- bb-2516
- bb-2516
- bb-2516
- marimastat
- marimastat
- marimastat
- marimastat
- marimastat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00261391 | Phase 1 | Oct 1, 2000 | Harvard University |
| NCT00003010 | Phase 3 | Sep 1, 1997 | Eastern Cooperative Oncology Group, Mayo Clinic, National Cancer Institute (NCI), North Central Cancer Treatment Group, Yeshiva University |
| NCT00003011 | Phase 3 | Mar 1, 1997 | Canadian Cancer Trials Group, Leiden University, University of Toronto |
| NCT00002911 | Phase 3 | Dec 1, 1996 | ILEX |
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 1997 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 1997 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| ILEX | For profit | 1 | 1 | 1 | 1996 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 1997 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 1997 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1997 |
| North Central Cancer Treatment Group | Academic/Hospital | 1 | 0 | 1 | 1997 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 1997 |
| Yeshiva University | Academic/Hospital | 1 | 0 | 1 | 1997 |